Aytu BioPharma, Inc. announced that Mark Oki will join Aytu as the company's chief financial officer effective January 17, 2022. Mr. Oki has spent over twenty years in financial leadership positions in the biotechnology and pharmaceutical industries across numerous development- and commercial-stage companies. Most recently, he served as chief financial officer of Vivus LLC, (formerly Vivus, Inc.), a commercial-stage pharmaceutical company with a portfolio of therapeutics and a late-stage rare disease development asset.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 USD | +0.63% | +8.84% | +12.68% |
05-15 | Transcript : Aytu BioPharma, Inc., Q3 2024 Earnings Call, May 15, 2024 | |
05-15 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q3 Revenue $18M, vs. Street Est of $17.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.68% | 17.82M | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- AYTU Stock
- News Aytu BioPharma, Inc.
- Aytu Biopharma, Inc. Appoints Mark Oki as Chief Financial Officer, Effective from January 17, 2022